140 related articles for article (PubMed ID: 21127410)
1. Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
Bommakanti SV; Dudek AZ; Khatri A; Kirstein MN; Gada PD
Am J Clin Oncol; 2011 Dec; 34(6):597-602. PubMed ID: 21127410
[TBL] [Abstract][Full Text] [Related]
2. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.
Luu T; Chow W; Lim D; Koczywas M; Frankel P; Cristea M; Margolin K; Doroshow JH; Somlo G; Gaur S; Yen Y; Morgan RJ
Anticancer Res; 2010 Jan; 30(1):167-74. PubMed ID: 20150632
[TBL] [Abstract][Full Text] [Related]
5. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
[TBL] [Abstract][Full Text] [Related]
6. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Falchook GS; Duvic M; Hong DS; Wheler J; Naing A; Lim J; Kurzrock R
Cancer Chemother Pharmacol; 2012 May; 69(5):1117-26. PubMed ID: 22205203
[TBL] [Abstract][Full Text] [Related]
7. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
Muscal JA; Thompson PA; Horton TM; Ingle AM; Ahern CH; McGovern RM; Reid JM; Ames MM; Espinoza-Delgado I; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2013 Mar; 60(3):390-5. PubMed ID: 22887890
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
[TBL] [Abstract][Full Text] [Related]
10. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
[TBL] [Abstract][Full Text] [Related]
11. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Portnow J; Frankel P; Koehler S; Twardowski P; Shibata S; Martel C; Morgan R; Cristea M; Chow W; Lim D; Chung V; Reckamp K; Leong L; Synold TW
Cancer Chemother Pharmacol; 2012 Feb; 69(2):505-14. PubMed ID: 21850464
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ
Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
Turkington RC; Purcell C; James CR; Millar J; Napier E; Law D; Gallagher R; Morris M; Wilson RH; Eatock MM
Invest New Drugs; 2014 Apr; 32(2):250-60. PubMed ID: 23665866
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
Pugh TJ; Chen C; Rabinovitch R; Eckhardt SG; Rusthoven KE; Swing R; Raben D
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):521-6. PubMed ID: 20133082
[TBL] [Abstract][Full Text] [Related]
17. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Ryan DP; O'Neil BH; Supko JG; Rocha Lima CM; Dees EC; Appleman LJ; Clark J; Fidias P; Orlowski RZ; Kashala O; Eder JP; Cusack JC
Cancer; 2006 Dec; 107(11):2688-97. PubMed ID: 17075878
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
Kouroukis CT; Fernandez LA; Crump M; Gascoyne RD; Chua NS; Buckstein R; Turner R; Assouline S; Klasa RJ; Walsh W; Powers J; Eisenhauer E
Leuk Lymphoma; 2011 Mar; 52(3):394-9. PubMed ID: 21323520
[TBL] [Abstract][Full Text] [Related]
19. Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.
Mehnert JM; Tan AR; Moss R; Poplin E; Stein MN; Sovak M; Levinson K; Lin H; Kane M; Gounder M; Lin Y; Shih WJ; White E; Rubin EH; Karantza V
Mol Cancer Ther; 2011 Aug; 10(8):1509-19. PubMed ID: 21680752
[TBL] [Abstract][Full Text] [Related]
20. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]